Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions

News Daily News

Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions

December 17, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

Women Stand to Gain the Most From Standardized STEMI Protocols

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

News Daily News

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

August 11, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.